Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 10/01/2019

DENOMINAZIONE FARMACO	PROCEDURA	ATC	PRINCIPIO ATTIVO	TITOLARE	PARERE CHMP	DECISIONE COMMISSIONE	DATA GUUE	data CTS	AIC	Confezione
Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva	EMEA/H/C/4250/IB/1	J05AR06	efavirenz/ emtricitabina/ tenofovir disoproxil	Zentiva, k.s.	20-nov-17	08-nov-18	27-dic-18	14-gen-19	045495025	2
XELJANZ	EMEA/H/C/4214/IAIN/14	L04AA29	Tofacitinib	Pfizer Europe MA EEIG	07-set-18	08-nov-18	27-dic-18	14-gen-19	045320102	14
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270295	29
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270307	30
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270319	31
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270321	32
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270333	33
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270345	34
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270358	35
Pregabalin Zentiva k.s	EMEA/H/C/4277/IA/5/G	N03AX16	pregabalin	Zentiva, k.s.	18-mag-18	28-nov-18	27-dic-18	14-gen-19	045270360	36
Wakix	EMEA/H/C/2616/IB/16	N07XX11	pitolisant cloridrato	Bioprojet Pharma	01-ago-18	22-nov-18	27-dic-18	14-gen-19	044839049	4
TAKHZYRO	EMEA/H/C/4806	B06AC05	lanadelumab	Shire Pharmaceuticals Ireland Limited	18-ott-18	22-nov-18	27-dic-18	14-gen-19	047417011	1
Jivi	EMEA/H/C/4054	B02BD02	damoctocog alfa pegol	Bayer AG	20-set-18	22-nov-18	27-dic-18	14-gen-19	047418013	1
Jivi	EMEA/H/C/4054	B02BD02	damoctocog alfa pegol	Bayer AG	20-set-18	22-nov-18	27-dic-18	14-gen-19	047418025	2
Jivi	EMEA/H/C/4054	B02BD02	damoctocog alfa pegol	Bayer AG	20-set-18	22-nov-18	27-dic-18	14-gen-19	047418037	3
Jivi	EMEA/H/C/4054	B02BD02	damoctocog alfa pegol	Bayer AG	20-set-18	22-nov-18	27-dic-18	14-gen-19	047418049	4
Jivi	EMEA/H/C/4054	B02BD02	damoctocog alfa pegol	Bayer AG	20-set-18	22-nov-18	27-dic-18	14-gen-19	047418052	5
Poteligeo	EMEA/H/C/4232	L01XC25	Mogamulizumab	Kyowa Kirin Holdings B.V.	20-set-18	22-nov-18	27-dic-18	14-gen-19	047420017	1
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416019	1
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416021	2
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416033	3
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416045	4
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416058	5
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416060	6
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416072	7
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416084	8
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416096	9
Alunbrig	EMEA/H/C/4248/	L01XE43	brigatinib	Takeda Pharma A/S	20-set-18	22-nov-18	27-dic-18	14-gen-19	047416108	10
GILENYA	EMEA/H/C/2202/X/44	L04AA27	Fingolimod	Novartis Europharm Limited	20-set-18	22-nov-18	27-dic-18	14-gen-19	040949075	7
GILENYA	EMEA/H/C/2202/X/44	L04AA27	Fingolimod	Novartis Europharm Limited	20-set-18	22-nov-18	27-dic-18	14-gen-19	040949087	8
Ziextenzo	EMEA/H/C/4802	L03AA13	pegfilgrastim	Sandoz GmbH	20-set-18	22-nov-18	27-dic-18	14-gen-19	047364017	1
Pifeltro	EMEA/H/C/4747	J05AG06	doravirina	Merck Sharp & Dohme B.V.	20-set-18	22-nov-18	27-dic-18	14-gen-19	047421019	1
Pifeltro	EMEA/H/C/4747	J05AG06	doravirina	Merck Sharp & Dohme B.V.	20-set-18	22-nov-18	27-dic-18	14-gen-19	047421021	2
Delstrigo	EMEA/H/C/4746	J05AG24	doravirina/lamivudina/tenofovir disoproxil	Merck Sharp & Dohme B.V.	20-set-18	22-nov-18	27-dic-18	14-gen-19	047426010	1
Delstrigo	EMEA/H/C/4746	J05AG24	doravirina/lamivudina/tenofovir disoproxil	Merck Sharp & Dohme B.V.	20-set-18	22-nov-18	27-dic-18	14-gen-19	047426022	2
Vabomere	EMEA/H/C/4669/	J01DH52	meropenem/vaborbactam	Rempex London Limited	20-set-18	20-nov-18	27-dic-18	14-gen-19	047422011	1
Apealea	EMEA/H/C/4154/	L01CD01	paclitaxel	Oasmia Pharmaceutical AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047399011	1
Pelmeg	EMEA/H/C/4700	L03AA13	pegfilgrastim	Cinfa Biotech S.L.	20-set-18	20-nov-18	27-dic-18	14-gen-19	047400015	1
Fulphila	EMEA/H/C/4915	L03AA13	pegfilgrastim	Mylan S.A.S.	20-set-18	20-nov-18	27-dic-18	14-gen-19	047401017	1
Fulphila	EMEA/H/C/4915	L03AA13	pegfilgrastim	Mylan S.A.S.	20-set-18	20-nov-18	27-dic-18	14-gen-19	047401029	2
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415017	1
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415029	2
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415031	3
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415043	4
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415056	5
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415068	6
Buvidal	EMEA/H/C/4651	N07BC01	Buprenorfina	Camurus AB	20-set-18	20-nov-18	27-dic-18	14-gen-19	047415070	7
Emgality	EMEA/H/C/4648	N02CX08	galcanezumab	Eli Lilly Nederland B.V.	20-set-18	14-nov-18	27-dic-18	14-gen-19	047424015	1
Emgality	EMEA/H/C/4648	N02CX08	galcanezumab	Eli Lilly Nederland B.V.	20-set-18	14-nov-18	27-dic-18	14-gen-19	047424027	2
Emgality	EMEA/H/C/4648	N02CX08	galcanezumab	Eli Lilly Nederland B.V.	20-set-18	14-nov-18	27-dic-18	14-gen-19	047424039	3

Lista dei farmaci in corso di valutazione per l'inserimento in Classe C(nn) - aggiornamento al 10/01/2019

Emgality	EMEA/H/C/4648	N02CX08	galcanezumab	Eli Lilly Nederland B.V.	20-set-18	14-nov-18	27-dic-18	14-gen-19	047424041	4
Benepali	EMEA/H/C/4007/IB/28/G	L04AB01	Etanercept	Samsung Bioepis NL B.V.	25-lug-17	08-nov-18	27-dic-18	14-gen-19	044691069	6
Benepali	EMEA/H/C/4007/IB/28/G	L04AB01	Etanercept	Samsung Bioepis NL B.V.	25-lug-17	08-nov-18	27-dic-18	14-gen-19	044691071	7
Luxturna	EMEA/H/C/4451	pending	voretigene neparvovec	Spark Therapeutics Ireland Ltd	20-set-18	22-nov-18	27-dic-18	14-gen-19	047423013	1
Slenyto	EMEA/H/C/4425/IB/1	N05CH01	melatonina	RAD Neurim Pharmaceuticals EEC Limited	14-nov-18	-	-	14-gen-19	047187051	5

La responsabilità di qualsiasi onere e/o attività che l' Azienda affronti utilizzando i codici AIC attribuiti alle confezioni (e inseriti nella Banca Dati del Farmaco-AIFA) precedentemente alla pubblicazione sulla Gazzetta Ufficiale della autorizzazione AIFA all' immissione in commercio del medicinale, è totalmente a carico dell' Azienda stessa. L' ufficialità dei codici AIC è subordinata alla pubblicazione degli stessi sulla Gazzetta Ufficiale, fino ad allora sono possibili, seppure improbabili, sue variazioni.